Literature DB >> 22567604

Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.

Debra L Safer1, Katherine D Arnow.   

Abstract

Duloxetine, a serotonin norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of depression, is used for off-label purposes such as treatment-resistant obsessive compulsive disorder, bulimia, and binge eating disorder. Although establishing a dose-response relationship for antidepressants in the treatment of depression is difficult, it is possible that for certain patterns of comorbidity, suprathreshold doses may be important to achieve remission. There is currently a paucity of literature regarding the use of suprathreshold doses of duloxetine in treatment refractory cases. This case report describes a clinical situation in which suprathreshold duloxetine was used to treat a patient with severe depression as well as co-morbid anorexia nervosa binge-purging type and obsessive compulsive disorder. One year after the initial increase to 180mg, the patient's mood remains improved. Our clinical account appears to be only the second case report describing the efficacy of high dose 180mg duloxetine in the management of symptoms refractory to treatment at standard doses.

Entities:  

Keywords:  Suprathreshold; anorexia nervosa; depression; duloxetine; obsessive-compulsive disorder

Year:  2012        PMID: 22567604      PMCID: PMC3342990     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  16 in total

1.  Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.

Authors:  M Machado; T R Einarson
Journal:  J Clin Pharm Ther       Date:  2010-04       Impact factor: 2.512

2.  High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.

Authors:  Yi-Wei Yeh; Chun-Hsiung Chen; Shin-Chang Kuo; Sheng-Chiang Wang; Chih-Kang Chen; Hui-Ming Feng
Journal:  Clin Neuropharmacol       Date:  2009 May-Jun       Impact factor: 1.592

Review 3.  Practice guideline for the treatment of patients with obsessive-compulsive disorder.

Authors:  Lorrin M Koran; Gregory L Hanna; Eric Hollander; Gerald Nestadt; Helen Blair Simpson
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

Review 4.  SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Authors:  Stephen M Stahl; Meghan M Grady; Chantal Moret; Mike Briley
Journal:  CNS Spectr       Date:  2005-09       Impact factor: 3.790

Review 5.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

6.  Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.

Authors:  Stephan Brecht; Durisala Desaiah; Elisete S Marechal; Ambra M Santini; Jana Podhorna; Julien D Guelfi
Journal:  J Clin Psychiatry       Date:  2010-09-21       Impact factor: 4.384

Review 7.  Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

Authors:  Bernardo Dell'Osso; Gerald Nestadt; Andrea Allen; Eric Hollander
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

8.  Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.

Authors:  Bernardo Dell'osso; Emanuela Mundo; Donatella Marazziti; A Carlo Altamura
Journal:  J Psychopharmacol       Date:  2008-01-21       Impact factor: 4.153

9.  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.

Authors:  Daniel Z Lieberman; Suena H Massey
Journal:  Core Evid       Date:  2010-06-15

10.  Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.

Authors:  Charles B Nemeroff; Richard Entsuah; Isma Benattia; Mark Demitrack; Diane M Sloan; Michael E Thase
Journal:  Biol Psychiatry       Date:  2007-09-24       Impact factor: 13.382

View more
  1 in total

Review 1.  Perplexities of treatment resistance in eating disorders.

Authors:  Katherine A Halmi
Journal:  BMC Psychiatry       Date:  2013-11-07       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.